Did You See Dedication In Medical Cannabis Payment Solutions (OTCMKTS:REFG)?

Nashville, TN – There is no doubt that the medical marijuana industry is promising to be a multi-billion dollar business. Medical Cannabis Payment Solutions (OTCMKTS:REFG) believes it has its share in the multi-billion dollar industry. That explains why the company is all over the map taking about its products, pipeline, and strategic arrangements. In a recent address to shareholders, the company’s CEO, Jeremy Roberts, sought to bring to the fore various achievements they have attained this year.

According to Roberts, Medical Cannabis Payment Solutions (OTCMKTS:REFG) is a dedicated, capable and focused company. The three words summarize the company in 2014, and the management believes that there is overwhelming evidence to support the claims.

Financial backing

One of the issues that the CEO highlighted in his open letter was that they have the finances to bankroll their operations. The company secured $500,000 funding to support its sales and marketing activities. Strong financial backing is important in the budding marijuana industry. As such, assurance over availability of the required financial resources means that the company can avoid excessive dilution of its stock to raise funds, a practice that is rampant in the marijuana industry.

In addition to the availability of funds, the CEO also stated that Medical Cannabis Payment Solutions (OTCMKTS:REFG) has a perfect assembly of professionals to drive forward its sales, marketing and overall growth agenda. Although REFG has its eyes on the long-term targets, it is structured its operations that they are also able to meet the short-term needs.

Product rollout

Roberts disclosed in his shareholder update that they had created a wide range of products targeting the marijuana industry. The further revealed that they were working with various government branches at state level to ensure a smooth launch of their products and solutions. One of the solutions they plan to launch is a payment service, which will be rollout out in states where marijuana businesses are already active.

Additionally, the company has plans for a mobile app to support sales, which it believes will boost online marijuana sales and increase customer access to the drug. In all these efforts, Medical Cannabis Payment Solutions (OTCMKTS:REFG) is geared towards generating sustainable revenue from diverse sources.


MENTOR CAPITAL, INC. (OTCMKTS:MNTR): Top Priority Issues In 2015

Nashville, TN – MENTOR CAPITAL, INC. (OTCMKTS:MNTR) expects to do a lot in 2015, especially by finishing the projects that are already underway. There is hope that the company could do better in the new year as it continues to focus on the budding marijuana industry. It has made several important moves this year that are expected to support better performance in the new year.

Among the issues that MENTOR CAPITAL, INC. (OTCMKTS:MNTR) expects to be of priority in 2015 is the completion of possible acquisitions in their pipeline. Additionally, the company disclosed its desire to increase capital to support further acquisitions and other cannabis investment. It will be seeking to raise capital from accredited and institutional investors.

Raising capital

According to the company’s CEO, Chet Billingsley, their fundraiser efforts have not come to zero this year. He revealed that they raised a fresh $3.6 million in capital this year, of which $1.8 million has already been deployed. Additionally, the CEO stated that they have a healthy cash reserve, which means that they hope to avoid excessive dilution of their stock. Most cannabis stocks are known for their excessive dilution of shares to raise capital, but that is something that MENTOR CAPITAL, INC. (OTCMKTS:MNTR) would want to avoid.

New auditor

Becoming a fully reporting company is another think that is being talked about at MENTOR CAPITAL, INC. (OTCMKTS:MNTR). The company hopes to become fully reporting with SEC in 2015. In a move that is related to becoming a fully reporting company, MNTR announced a change in its auditors. It cut links with Albert Wong & Co., which is a New York auditor and tapped BF Borgers CPA PC of Colorado to be its new auditor.

According to the management of MENTOR CAPITAL, INC. (OTCMKTS:MNTR), the move supports their full reporting agenda. Additionally, it makes sense for the company now with its focus on medical marijuana, to have an auditor in a state that has many active cannabis businesses.


BREEDIT CORP (OTCMKTS:BRDT): A Unique Entry Point Into Marijuana Industry

Nashville, TN – Entrepreneurs have found different entry points into the budding marijuana industry. However, BREEDIT CORP (OTCMKTS:BRDT) is a bit more different from everyone else in the medical cannabis field. The company boasts propriety agro-breeding solutions, but the question is, can the company convert its research efforts into money?

It doesn’t matter how much a company dominates the news headlines. Investors always look to the value beyond the hype, and that is the issue that now confronts BREEDIT CORP (OTCMKTS:BRDT). The company has this year announced various accomplishments. For example, it announced a joint venture with an Israeli company towards the development of new strains of cannabis.

New cannabis strains

A few months later, the joint venture, which is known as KanaboSeed Ltd, said that it submitted applications to register two varieties of marijuana. The application was submitted to the Rights Council of Israeli Ministry of Agriculture and Development.

All along, BREEDIT CORP (OTCMKTS:BRDT) has sought to distinguish itself from other players in the medical marijuana industry. According to the company, there is a need to develop desired strains of cannabis. New varieties of marijuana are important when it comes to addressing certain specific medical needs. Therefore, the company’s efforts in the research and development of new cannabis strains have been promoted by the requests from doctors and other practitioners.

Huge opportunity

When BREEDIT CORP (OTCMKTS:BRDT) made the application for the registration of new varieties of cannabis in Israel this year, the management also said that that was just the beginning of things. According to the company, the commercialization of marijuana has created the need for new strains that promise more medical uses, which is an area in which they hope to deliver perfectly.

Developing of new cannabis strains not only helps the company to support expanded medical application of cannabis, but also opens up new revenue opportunities. The company also gets to fetch crucial patents that can be monetized as medical marijuana industry grows.



Nashville, TN – Marijuana focused companies have several things in common regardless of their level of entry into the nascent industry. One such common feature among cannabis companies is that they aim to keep investors informed in every step they make. CANNABUSINESS GROUP (OTCMKTS:CBGI) is one typical marijuana company that has been trying to keep its shareholders posted over its progress in the industry. So, what are some of the issues that the company has been talking about this year?

Creating shareholder value

Improving shareholder value is a core issue at CANNABUSINESS GROUP (OTCMKTS:CBGI). The company this year discussed how it hopes to create or value for its shareholders by spinning off some of the businesses it holds or merging them with third-party companies.

CANNABUSINESS GROUP (OTCMKTS:CBGI)’s approach in the marijuana industry is the acquisition of companies that offer products and services in the cannabis field. Its areas of focus include security services, e-commerce, software solutions and dispensary operations. The company is trying to capture as many sectors of the budding cannabis industry so that it can deliver maximum shareholder value.

Management shakeup

Besides making key acquisitions this year and discussion its growth plan, the company also talked about changes at the management level and headquarters address. For example, the company’s CEO and Chairman, Michael Cummings, resigned his position over health issues. He was replaced by Jeff Jiron. Commenting on his exit, Cumming stated that is health condition could not allow him to dedicate the required time for the operations of CANNABUSINESS GROUP (OTCMKTS:CBGI).

The management shakeup at CBGI was significant in more than one way. It saw a key leader of the company bowing out at a very crucial moment. However, it also meant that the company’s operations would not be hurt by the health issue of its foremost leader.

CANNABUSINESS GROUP (OTCMKTS:CBGI) this year announced the relocation of its headquarters address to Irvine, California.

The company announced plans to raise $5 million through a private placement.


Insys Therapeutics Inc (NASDAQ:INSY): Something To Show For Improved Research Spending

Nashville, TN – Insys Therapeutics Inc (NASDAQ:INSY) is spending a lot of money in research and development projects. The company does so to boost its product pipeline with the hope of diversifying its revenue stream and improving overall performance. It is important to note that positive things have come from the company’s multiple research programs, including a recent orphan drug designation by the Food and Drug Administration (FDA).

Bump in research spending

In its 3Q update, the company disclosed significant increase in research and development investment this year compared with the previous one. For example, the company invested $7 million in research and development in 3Q2014 compared with $1.7 million in 3Q2013. The improved spending on research and development by Insys Therapeutics Inc (NASDAQ:INSY) has not come to nothing. Several gains have been made in the research and development front with certain drug candidate products attractive favorable designation from the regulator.

The company recently received an orphan drug designation from the FDA for its cancer formulation that makes cancer drugs more soluble. Therefore, the formulation helps with the delivery of gastric cancer drugs, which are fat-based. Although the formulation is currently not approved by the regulator, the orphan drug designation comes as a much-needed boost towards the commercialization of the product.

Financial highlight

Insys Therapeutics Inc (NASDAQ:INSY) has an approved product known as Subsys, which is a painkiller whose use is currently limited by the FDA to cancer patients. However, Subsys is the top revenue earner for the company. Subsys brought in $58.2 million in sales in 3Q, in a quarter that had total net revenue of $58.3 million. Revenue from Subsys increased from $28.4 million in the comparable quarter in the previous year. Total net revenue was up 100% from the prior year.

According to Insys Therapeutics Inc (NASDAQ:INSY)’s CEO, Mike Babich, their efforts are geared towards generating more revenue from the already approved products and diversifying revenue streams through multiple research and development projects.

Pin It on Pinterest